{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T10:52:17Z","timestamp":1762253537471,"version":"3.44.0"},"reference-count":156,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.ejphar.2020.173568","type":"journal-article","created":{"date-parts":[[2020,9,18]],"date-time":"2020-09-18T22:44:20Z","timestamp":1600469060000},"page":"173568","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["A review of medications used to control and improve the signs and symptoms of COVID-19 patients"],"prefix":"10.1016","volume":"887","author":[{"given":"Kiavash","family":"Hushmandi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saied","family":"Bokaie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehrdad","family":"Hashemi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ebrahim Rahmani","family":"Moghadam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehdi","family":"Raei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farid","family":"Hashemi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahdi","family":"Bagheri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Solomon","family":"Habtemariam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seyed Mohammad","family":"Nabavi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2020","author":"Adem","series-title":"Identification of Potent COVID-19 Main Protease (Mpro) Inhibitors from Natural Polyphenols: an in Silico Strategy Unveils a Hope against CORONA","key":"10.1016\/j.ejphar.2020.173568_bib1"},{"year":"2020","author":"Adepoju","series-title":"Tuberculosis and HIV Responses Threatened by COVID-19. Lancet HIV","key":"10.1016\/j.ejphar.2020.173568_bib2"},{"key":"10.1016\/j.ejphar.2020.173568_bib3","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00221-18","article-title":"Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease","volume":"9","author":"Agostini","year":"2018","journal-title":"mBio"},{"key":"10.1016\/j.ejphar.2020.173568_bib4","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00221-18","article-title":"Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease","volume":"9","author":"Agostini","year":"2018","journal-title":"mBio"},{"key":"10.1016\/j.ejphar.2020.173568_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.tmaid.2020.101615","article-title":"Remdesivir as a possible therapeutic option for the COVID-19","author":"Al-Tawfiq","year":"2020","journal-title":"Trav. Med. Infect. Dis."},{"key":"10.1016\/j.ejphar.2020.173568_bib6","first-page":"1","article-title":"Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19)","author":"Alhazzani","year":"2020","journal-title":"Intensive Care Med."},{"key":"10.1016\/j.ejphar.2020.173568_bib7","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0102436","article-title":"Tocilizumab, a proposed therapy for the cachexia of Interleukin6-expressing lung cancer","volume":"9","author":"Ando","year":"2014","journal-title":"PloS One"},{"issue":"7","key":"10.1016\/j.ejphar.2020.173568_bib8","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/S1473-3099(20)30264-4","article-title":"From China: hope and lessons for COVID-19 control","volume":"20","author":"Azman","year":"2020","journal-title":"Lancet Infect. Dis."},{"issue":"19","key":"10.1016\/j.ejphar.2020.173568_bib9","first-page":"1851","article-title":"Covid-19\u2014the search for effective therapy","volume":"382","author":"Baden","year":"2020","journal-title":"Mass Med. Soc."},{"issue":"7","key":"10.1016\/j.ejphar.2020.173568_bib10","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1021\/acschemneuro.0c00122","article-title":"Evidence of the COVID-19 virus targeting the CNS: tissue distribution, host\u2013virus interaction, and proposed neurotropic mechanisms","volume":"11","author":"Baig","year":"2020","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.ejphar.2020.173568_bib11","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.1128\/JVI.02346-12","article-title":"T-705 (favipiravir) induces lethal mutagenesis in influenza A H1N1 viruses in vitro","volume":"87","author":"Baranovich","year":"2013","journal-title":"J. Virol."},{"key":"10.1016\/j.ejphar.2020.173568_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2020.104659","article-title":"New therapeutic opportunities for COVID-19 patients with Tocilizumab: possible correlation of interleukin-6 receptor inhibitors with osteonecrosis of the jaws","author":"Bennardo","year":"2020","journal-title":"Oral Oncol."},{"key":"10.1016\/j.ejphar.2020.173568_bib13","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1021\/jm0601856","article-title":"Design and synthesis of hydroxyferroquine derivatives with antimalarial and antiviral activities","volume":"49","author":"Biot","year":"2006","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejphar.2020.173568_bib14","first-page":"1","article-title":"TMPRSS2-Inhibitors play a role in cell entry mechanism of COVID-19: an insight into camostat and nefamostat","volume":"2","author":"Bittmann","year":"2020","journal-title":"J. Regen. Biol. Med."},{"key":"10.1016\/j.ejphar.2020.173568_bib15","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.antiviral.2017.12.021","article-title":"Efficacy of favipiravir (T-705) in nonhuman primates infected with Ebola virus or Marburg virus","volume":"151","author":"Bixler","year":"2018","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejphar.2020.173568_bib16","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.antiviral.2003.12.002","article-title":"Lopinavir\/ritonavir vs. indinavir\/ritonavir in antiretroviral naive HIV-infected patients: immunovirological outcome and side effects","volume":"62","author":"Bongiovanni","year":"2004","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejphar.2020.173568_bib17","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00669-19","article-title":"Lethal mutagenesis of Rift Valley fever virus induced by favipiravir","volume":"63","author":"Borrego","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"issue":"6","key":"10.1016\/j.ejphar.2020.173568_bib18","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1056\/NEJMoa2016638","article-title":"A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19","volume":"383","author":"Boulware","year":"2020","journal-title":"N. Engl. J. Med."},{"year":"2020","author":"Cai","series-title":"Experimental Treatment with Favipiravir for COVID-19: an Open-Label Control Study","key":"10.1016\/j.ejphar.2020.173568_bib19"},{"year":"2020","author":"Campbell","series-title":"Will Complement Inhibition Be the New Target in Treating COVID-19 Related Systemic Thrombosis? Circulation","key":"10.1016\/j.ejphar.2020.173568_bib20"},{"issue":"15","key":"10.1016\/j.ejphar.2020.173568_bib23","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1093\/cid\/ciaa243","article-title":"Clinical features and short-term outcomes of 102 patients with corona virus disease 2019 in wuhan, China","volume":"71","author":"Cao","year":"2020","journal-title":"Clin. Infect. Dis."},{"issue":"19","key":"10.1016\/j.ejphar.2020.173568_bib21","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1056\/NEJMoa2001282","article-title":"A trial of lopinavir\u2013ritonavir in adults hospitalized with severe Covid-19","volume":"382","author":"Cao","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"19","key":"10.1016\/j.ejphar.2020.173568_bib22","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1056\/NEJMoa2001282","article-title":"A trial of lopinavir-ritonavir in adults hospitalized with severe covid-19","volume":"382","author":"Cao","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2020.173568_bib24","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s13054-020-02851-4","article-title":"A new clinical trial to test high-dose vitamin C in patients with COVID-19","volume":"24","author":"Carr","year":"2020","journal-title":"Crit. Care"},{"key":"10.1016\/j.ejphar.2020.173568_bib25","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1172\/JCI138003","article-title":"The convalescent sera option for containing COVID-19","volume":"130","author":"Casadevall","year":"2020","journal-title":"J. Clin. Invest."},{"issue":"5","key":"10.1016\/j.ejphar.2020.173568_bib26","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.diii.2020.03.010","article-title":"Favorable changes of CT findings in a patient with COVID-19 pneumonia after treatment with tocilizumab","volume":"101","author":"Cellina","year":"2020","journal-title":"Diag. Interv. Imag."},{"key":"10.1016\/j.ejphar.2020.173568_bib27","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1093\/infdis\/jiv392","article-title":"Treatment with lopinavir\/ritonavir or interferon-\u03b21b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset","volume":"212","author":"Chan","year":"2015","journal-title":"J. Infect Dis."},{"issue":"2 & 3","key":"10.1016\/j.ejphar.2020.173568_bib28","first-page":"147","article-title":"The 2019 novel coronavirus disease (COVID-19) pandemic: a review of the current evidence","volume":"151","author":"Chatterjee","year":"2020","journal-title":"Indian J. Med. Res."},{"issue":"5","key":"10.1016\/j.ejphar.2020.173568_bib29","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.kint.2020.03.005","article-title":"Kidney disease is associated with in-hospital death of patients with COVID-19","volume":"97","author":"Cheng","year":"2020","journal-title":"Kidney Int."},{"key":"10.1016\/j.ejphar.2020.173568_bib30","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1136\/thorax.2003.012658","article-title":"Role of lopinavir\/ritonavir in the treatment of SARS: initial virological and clinical findings","volume":"59","author":"Chu","year":"2004","journal-title":"Thorax"},{"key":"10.1016\/j.ejphar.2020.173568_bib31","first-page":"1","article-title":"COVID-19 outbreak: an overview","author":"Ciotti","year":"2020","journal-title":"Chemotherapy"},{"issue":"20","key":"10.1016\/j.ejphar.2020.173568_bib32","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1161\/CIRCULATIONAHA.120.046941","article-title":"Coronavirus disease 2019 (COVID-19) and cardiovascular disease","volume":"141","author":"Clerkin","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.ejphar.2020.173568_bib33","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1053\/jinf.2001.0928","article-title":"Iatrogenic Cushing's syndrome in an HIV-infected patient treated with inhaled corticosteroids (fluticasone propionate) and low dose ritonavir enhanced PI containing regimen","volume":"44","author":"Clevenbergh","year":"2002","journal-title":"J. Infect."},{"key":"10.1016\/j.ejphar.2020.173568_bib34","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.autrev.2019.05.007","article-title":"Challenges in the treatment of rheumatoid arthritis","volume":"18","author":"Conigliaro","year":"2019","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.ejphar.2020.173568_bib35","doi-asserted-by":"crossref","first-page":"3962","DOI":"10.1002\/asia.201900841","article-title":"New nucleoside analogues for the treatment of hemorrhagic fever virus infections","volume":"14","author":"De Clercq","year":"2019","journal-title":"Chem. Asian J."},{"issue":"7","key":"10.1016\/j.ejphar.2020.173568_bib36","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1002\/ajh.25833","article-title":"Rapid and severe covid-19 pneumonia with severe acute chest syndrome in a sickle cell patient successfully treated with tocilizumab","volume":"95","author":"De Luna","year":"2020","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.ejphar.2020.173568_bib37","doi-asserted-by":"crossref","first-page":"6771","DOI":"10.1073\/pnas.1922083117","article-title":"Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection","volume":"117","author":"de Wit","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejphar.2020.173568_bib38","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1093\/jac\/dku209","article-title":"Mutations in the chikungunya virus non-structural proteins cause resistance to favipiravir (T-705), a broad-spectrum antiviral","volume":"69","author":"Delang","year":"2014","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ejphar.2020.173568_bib39","doi-asserted-by":"crossref","first-page":"58","DOI":"10.5582\/ddt.2020.01012","article-title":"Discovering drugs to treat coronavirus disease 2019 (COVID-19)","volume":"14","author":"Dong","year":"2020","journal-title":"Drug Discov. Ther."},{"key":"10.1016\/j.ejphar.2020.173568_bib40","first-page":"171","article-title":"First newborn baby to receive experimental therapies survives Ebola virus disease","volume":"215","author":"D\u00f6rnemann","year":"2017","journal-title":"J. Infect Dis."},{"issue":"18","key":"10.1016\/j.ejphar.2020.173568_bib41","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1016\/j.jacc.2020.03.031","article-title":"Cardiovascular considerations for patients, health care workers, and health systems during the coronavirus disease 2019 (COVID-19) pandemic","volume":"75","author":"Driggin","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"issue":"2","key":"10.1016\/j.ejphar.2020.173568_bib42","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/cpt.1844","article-title":"Favipiravir: pharmacokinetics and concerns about clinical trials for 2019-nCoV infection","volume":"108","author":"Du","year":"2020","journal-title":"Clin. Pharmacol. Ther."},{"year":"2020","author":"Elfiky","series-title":"Anti-HCV, Nucleotide Inhibitors, Repurposing against COVID-19","key":"10.1016\/j.ejphar.2020.173568_bib43"},{"year":"2020","author":"Elfiky","series-title":"Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA Dependent RNA Polymerase (RdRp): A Molecular Docking Study","key":"10.1016\/j.ejphar.2020.173568_bib44"},{"key":"10.1016\/j.ejphar.2020.173568_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2019.107735","article-title":"Biomarkers for epileptogenesis and its treatment","volume":"167","author":"Engel","year":"2020","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejphar.2020.173568_bib46","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01400-17","article-title":"Extinction of West Nile virus by favipiravir through lethal mutagenesis","volume":"61","author":"Escribano-Romero","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"issue":"7","key":"10.1016\/j.ejphar.2020.173568_bib47","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1016\/j.cgh.2020.04.002","article-title":"Clinical features of COVID-19-related liver Functional Abnormality","volume":"18","author":"Fan","year":"2020","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"2","key":"10.1016\/j.ejphar.2020.173568_bib48","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.jhin.2020.04.008","article-title":"Preventing the transmission of COVID-19 amongst healthcare workers","volume":"105","author":"Feng Tan","year":"2020","journal-title":"J. Hosp. Infect."},{"volume":"vol. 4","year":"2015","author":"Fink","key":"10.1016\/j.ejphar.2020.173568_bib49"},{"year":"2020","series-title":"FDA Cautions against Use of Hydroxychloroquine or Chloroquine for COVID-19 outside of the Hospital Setting or a Clinical Trial Due to Risk of Heart Rhythm Problems. Food and Drug Administration","key":"10.1016\/j.ejphar.2020.173568_bib50"},{"key":"10.1016\/j.ejphar.2020.173568_bib51","article-title":"Temporal clinical and laboratory response to interleukin-6 receptor blockade with Tocilizumab in 89 hospitalized patients with COVID-19 pneumonia","author":"Formina","year":"2020","journal-title":"medRxiv"},{"key":"10.1016\/j.ejphar.2020.173568_bib52","doi-asserted-by":"crossref","first-page":"11440","DOI":"10.1128\/JVI.76.22.11440-11446.2002","article-title":"Inhibition of endosomal\/lysosomal degradation increases the infectivity of human immunodeficiency virus","volume":"76","author":"Fredericksen","year":"2002","journal-title":"J. Virol."},{"key":"10.1016\/j.ejphar.2020.173568_bib53","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.antiviral.2013.09.015","article-title":"Favipiravir (T-705), a novel viral RNA polymerase inhibitor","volume":"100","author":"Furuta","year":"2013","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejphar.2020.173568_bib54","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.antiviral.2009.02.198","article-title":"T-705 (favipiravir) and related compounds: novel broad-spectrum inhibitors of RNA viral infections","volume":"82","author":"Furuta","year":"2009","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejphar.2020.173568_bib55","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.antiviral.2009.02.198","article-title":"T-705 (favipiravir) and related compounds: novel broad-spectrum inhibitors of RNA viral infections","volume":"82","author":"Furuta","year":"2009","journal-title":"Antivir. Res."},{"issue":"1","key":"10.1016\/j.ejphar.2020.173568_bib56","doi-asserted-by":"crossref","first-page":"72","DOI":"10.5582\/bst.2020.01047","article-title":"Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies","volume":"14","author":"Gao","year":"2020","journal-title":"Biosci. Trends"},{"key":"10.1016\/j.ejphar.2020.173568_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105949","article-title":"Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial","author":"Gautret","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.ejphar.2020.173568_bib58","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1051\/parasite\/2001084363","article-title":"Short-term effect of chloroquine on the infectivity of Plasmodium chabaudi gametocytes","volume":"8","author":"Gautret","year":"2001","journal-title":"Parasite"},{"key":"10.1016\/j.ejphar.2020.173568_bib59","doi-asserted-by":"crossref","first-page":"4773","DOI":"10.1074\/jbc.AC120.013056","article-title":"The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus","volume":"295","author":"Gordon","year":"2020","journal-title":"J. Biol. Chem."},{"issue":"24","key":"10.1016\/j.ejphar.2020.173568_bib60","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1056\/NEJMoa2007016","article-title":"Compassionate use of remdesivir for patients with severe covid-19","volume":"382","author":"Grein","year":"2020","journal-title":"N. Engl. J. Med."},{"year":"2015","author":"Grobusch\u2013mp","series-title":"Ebola Virus Disease: Basics the Medical Specialist Should Know","key":"10.1016\/j.ejphar.2020.173568_bib61"},{"year":"2020","author":"Gu","series-title":"COVID-19: Gastrointestinal Manifestations and Potential Fecal-Oral Transmission","key":"10.1016\/j.ejphar.2020.173568_bib62"},{"key":"10.1016\/j.ejphar.2020.173568_bib63","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002535","article-title":"Antiviral efficacy of favipiravir against Ebola virus: a translational study in cynomolgus macaques","volume":"15","author":"Guedj","year":"2018","journal-title":"PLoS Med."},{"issue":"2","key":"10.1016\/j.ejphar.2020.173568_bib64","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.ejphar.2020.173568_bib65","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S0140-6736(16)30386-5","article-title":"Late Ebola virus relapse causing meningoencephalitis: a case report","volume":"388","author":"Jacobs","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2020.173568_bib66","first-page":"140","article-title":"Coronavirus (COVID-19): history, current knowledge and pipeline medications","volume":"4","author":"Jahangir","year":"2020","journal-title":"Int. J. Pharm. Pharmacol."},{"key":"10.1016\/j.ejphar.2020.173568_bib67","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0068347","article-title":"The ambiguous base-pairing and high substrate efficiency of T-705 (favipiravir) ribofuranosyl 5\u2032-triphosphate towards influenza A virus polymerase","volume":"8","author":"Jin","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.ejphar.2020.173568_bib68","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1136\/ard.2008.105197","article-title":"Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study","volume":"69","author":"Jones","year":"2010","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.ejphar.2020.173568_bib69","article-title":"A comprehensive literature review on the clinical presentation, and management of the pandemic coronavirus disease 2019 (COVID-19)","volume":"12","author":"Kakodkar","year":"2020","journal-title":"Cureus"},{"key":"10.1016\/j.ejphar.2020.173568_bib70","series-title":"Nterpreting COVID-19 and Virtual Care Trends: A Call for Action","article-title":"I","author":"Khairat","year":"2020"},{"issue":"4","key":"10.1016\/j.ejphar.2020.173568_bib71","doi-asserted-by":"crossref","first-page":"105933","DOI":"10.1016\/j.ijantimicag.2020.105933","article-title":"Arguments in favour of remdesivir for treating SARS-CoV-2 infections","volume":"55","author":"Ko","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.ejphar.2020.173568_bib72","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105933","article-title":"Arguments in favour of remdesivir for treating SARS-CoV-2 infections","author":"Ko","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.ejphar.2020.173568_bib73","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1001\/jama.2013.283495","article-title":"More evidence emerges that bats may have spread SARS","volume":"310","author":"Kuehn","year":"2013","journal-title":"J. Am. Med. Assoc."},{"year":"2020","author":"Kujawski","series-title":"First 12 Patients with Coronavirus Disease 2019 (COVID-19) in the United States. medRxiv","key":"10.1016\/j.ejphar.2020.173568_bib74"},{"key":"10.1016\/j.ejphar.2020.173568_bib75","doi-asserted-by":"crossref","DOI":"10.1038\/d41586-020-01824-5","article-title":"Coronavirus breakthrough: dexamethasone is first drug shown to save lives","volume":"582","author":"Ledford","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.ejphar.2020.173568_bib76","first-page":"2","article-title":"Current evidence and research prospects of Xuebijing injection in treating novel coronavirus-infected pneumonia (COVID-19)","author":"Li","year":"2020","journal-title":"World Sci. Technol. Modern. Tradit. Chin. Med. Mater. Med."},{"year":"2020","author":"Li","series-title":"Therapeutic Options for the 2019 Novel Coronavirus (2019-nCoV)","key":"10.1016\/j.ejphar.2020.173568_bib77"},{"key":"10.1016\/j.ejphar.2020.173568_bib78","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s13643-020-01343-4","article-title":"Traditional Chinese herbal medicine for treating novel coronavirus (COVID-19) pneumonia: protocol for a systematic review and meta-analysis","volume":"9","author":"Li","year":"2020","journal-title":"Syst. Rev."},{"issue":"15","key":"10.1016\/j.ejphar.2020.173568_bib79","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1093\/cid\/ciaa242","article-title":"Analysis of epidemiological and clinical features in older patients with corona virus disease 2019 (COVID-19) out of wuhan","volume":"71","author":"Lian","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ejphar.2020.173568_bib80","article-title":"Case of the index patient who caused tertiary transmission of COVID-19 infection in Korea: the application of lopinavir\/ritonavir for the treatment of COVID-19 infected pneumonia monitored by quantitative RT-PCR","volume":"35","author":"Lim","year":"2020","journal-title":"J. Kor. Med. Sci."},{"key":"10.1016\/j.ejphar.2020.173568_bib81","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s12879-017-2253-8","article-title":"Effective inhibition of MERS-CoV infection by resveratrol","volume":"17","author":"Lin","year":"2017","journal-title":"BMC Infect. Dis."},{"issue":"2","key":"10.1016\/j.ejphar.2020.173568_bib82","first-page":"119","article-title":"Critically ill patients with COVID-19 in Hong Kong: a multicentre retrospective observational cohort study","volume":"22","author":"Ling","year":"2020","journal-title":"Crit. Care Resusc."},{"key":"10.1016\/j.ejphar.2020.173568_bib83","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aau9242","article-title":"Remdesivir (GS-5734) protects African green monkeys from Nipah virus challenge","volume":"11","author":"Lo","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ejphar.2020.173568_bib84","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.tim.2015.06.003","article-title":"Bat-to-human: spike features determining \u2018host jump\u2019of coronaviruses SARS-CoV, MERS-CoV, and beyond","volume":"23","author":"Lu","year":"2015","journal-title":"Trends Microbiol."},{"issue":"6","key":"10.1016\/j.ejphar.2020.173568_bib85","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1002\/jmv.25761","article-title":"The potential chemical structure of anti-SARS-CoV-2 RNA-dependent RNA polymerase","volume":"92","author":"Lung","year":"2020","journal-title":"J. Med. Virol."},{"issue":"7","key":"10.1016\/j.ejphar.2020.173568_bib86","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1002\/jmv.25801","article-title":"Tocilizumab treatment in COVID-19: a single center experience","volume":"92","author":"Luo","year":"2020","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.ejphar.2020.173568_bib87","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104758","article-title":"Ribavirin does not potentiate favipiravir antiviral activity against Ebola virus in non-human primates","volume":"177","author":"Madelain","year":"2020","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejphar.2020.173568_bib88","first-page":"58","article-title":"Optimisation of vitamin D status for enhanced immuno-protection against covid-19","volume":"113","author":"McCartney","year":"2020","journal-title":"Ir. Med. J."},{"key":"10.1016\/j.ejphar.2020.173568_bib89","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/irv.12047","article-title":"Influenza neuraminidase inhibitors: antiviral action and mechanisms of resistance","volume":"7","author":"McKimm\u2010Breschkin","year":"2013","journal-title":"Influ. Respir. Viruses"},{"issue":"7","key":"10.1016\/j.ejphar.2020.173568_bib90","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.annonc.2020.03.300","article-title":"Tocilizumab, an anti-IL6 receptor antibody, to treat Covid-19-related respiratory failure: a case report","volume":"31","author":"Michot","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ejphar.2020.173568_bib91","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3109\/00498259409043223","article-title":"Metabolic fate of 14C-camostat mesylate in man, rat and dog after intravenous administration","volume":"24","author":"Midgley","year":"1994","journal-title":"Xenobiotica"},{"issue":"5","key":"10.1016\/j.ejphar.2020.173568_bib92","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1136\/annrheumdis-2020-217442","article-title":"COVID-19 in a patient with systemic sclerosis treated with tocilizumab for SSc-ILD","volume":"79","author":"Mihai","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.ejphar.2020.173568_bib93","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2165\/00003088-200746010-00005","article-title":"Lopinavir\/ritonavir pharmacokinetics in HIV and hepatitis C virus Co-infected patients without liver function impairment","volume":"46","author":"Molto","year":"2007","journal-title":"Clin. Pharmacokinet."},{"issue":"5","key":"10.1016\/j.ejphar.2020.173568_bib94","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s40264-020-00933-4","article-title":"Chloroquine for COVID-19 infection","volume":"43","author":"Moore","year":"2020","journal-title":"Drug Saf."},{"key":"10.1016\/j.ejphar.2020.173568_bib95","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1124\/mol.113.087247","article-title":"Role of human hypoxanthine guanine phosphoribosyltransferase in activation of the antiviral agent T-705 (favipiravir)","volume":"84","author":"Naesens","year":"2013","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.ejphar.2020.173568_bib96","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1053\/gast.2001.24832","article-title":"Prevention of rat hepatic fibrosis by the protease inhibitor, camostat mesilate, via reduced generation of active TGF-\u03b2","volume":"120","author":"Okuno","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejphar.2020.173568_bib97","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1093\/jac\/dky560","article-title":"Optimizing T-705 (favipiravir) treatment of severe influenza B virus infection in the immunocompromised mouse model","volume":"74","author":"Pascua","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"issue":"6","key":"10.1016\/j.ejphar.2020.173568_bib98","doi-asserted-by":"crossref","first-page":"e221","DOI":"10.1016\/j.jaad.2020.04.017","article-title":"Hydroxychloroquine and ivermectin: a synergistic combination for COVID-19 chemoprophylaxis and\/or treatment?","volume":"82","author":"Patri","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.ejphar.2020.173568_bib99","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1177\/1098612X19825701","article-title":"Efficacy and safety of the nucleoside analog GS-441524 for treatment of cats with naturally occurring feline infectious peritonitis","volume":"21","author":"Pedersen","year":"2019","journal-title":"J. Feline Med. Surg."},{"key":"10.1016\/j.ejphar.2020.173568_bib100","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1161\/CIRCULATIONAHA.104.528695","article-title":"Angiotensin-converting enzyme inhibitors: a new mechanism of action","volume":"112","author":"Peng","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.ejphar.2020.173568_bib101","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1089\/gen.40.04.02","article-title":"COVID-19: top 60 Drug Treatments in Development: the biopharma industry is ramping up the development of dozens of potential drug therapies and clinical testing in an all-hands effort to combat the pandemic","volume":"40","author":"Philippidis","year":"2020","journal-title":"Gene. Eng. Biotechnol. News"},{"unstructured":"Prime, B., FDA Approves Amgen's Repatha\u00ae(evolocumab) to Prevent Heart Attack and Stroke.","key":"10.1016\/j.ejphar.2020.173568_bib102"},{"key":"10.1016\/j.ejphar.2020.173568_bib103","first-page":"399","article-title":"Treatment of severe acute respiratory syndrome with lopinavir\/ritonavir: a multicentre retrospective matched cohort study","volume":"9","author":"Que","year":"2003","journal-title":"Hong Kong Med. J."},{"key":"10.1016\/j.ejphar.2020.173568_bib104","first-page":"174","article-title":"SARS-CoV-2, SARS-CoV, and MERS-COV: a comparative overview","volume":"28","author":"Rabaan","year":"2020","journal-title":"Inf. Med."},{"issue":"9","key":"10.1016\/j.ejphar.2020.173568_bib105","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/S1473-3099(20)30270-X","article-title":"Baricitinib for COVID-19: a suitable treatment? - authors\u2019 reply","volume":"20","author":"Richardson","year":"2020","journal-title":"Lancet Infect. Dis."},{"issue":"16","key":"10.1016\/j.ejphar.2020.173568_bib106","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1001\/jama.2020.4940","article-title":"Convalescent plasma to treat COVID-19: possibilities and challenges","volume":"323","author":"Roback","year":"2020","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.ejphar.2020.173568_bib107","doi-asserted-by":"crossref","first-page":"e40","DOI":"10.26633\/RPSP.2020.40","article-title":"Clinical trials on drug repositioning for COVID-19 treatment","volume":"44","author":"Rosa","year":"2020","journal-title":"Rev. Panam. Salud P\u00fablic"},{"key":"10.1016\/j.ejphar.2020.173568_bib108","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.3332\/ecancer.2020.1022","article-title":"Associations between immune-suppressive and stimulating drugs and novel COVID-19-a systematic review of current evidence","volume":"14","author":"Russell","year":"2020","journal-title":"Ecancermedicalscience"},{"key":"10.1016\/j.ejphar.2020.173568_bib109","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/S1473-3099(03)00806-5","article-title":"Effects of chloroquine on viral infections: an old drug against today's diseases","volume":"3","author":"Savarino","year":"2003","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.ejphar.2020.173568_bib110","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.antiviral.2014.01.016","article-title":"Favipiravir (T-705) protects against peracute Rift Valley fever virus infection and reduces delayed-onset neurologic disease observed with ribavirin treatment","volume":"104","author":"Scharton","year":"2014","journal-title":"Antivir. Res."},{"year":"2020","author":"Schilling","series-title":"Coping with Covid-19 Coronavirus","key":"10.1016\/j.ejphar.2020.173568_bib111"},{"key":"10.1016\/j.ejphar.2020.173568_bib112","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.antiviral.2018.10.026","article-title":"Favipiravir inhibits in vitro Usutu virus replication and delays disease progression in an infection model in mice","volume":"160","author":"Segura Guerrero","year":"2018","journal-title":"Antivir. Res."},{"year":"2020","author":"Shah","series-title":"In Silico Studies on Therapeutic Agents for COVID-19: Drug Repurposing Approach","key":"10.1016\/j.ejphar.2020.173568_bib113"},{"key":"10.1016\/j.ejphar.2020.173568_bib114","first-page":"10","article-title":"Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19)","volume":"38","author":"Shanmugaraj","year":"2020","journal-title":"Asian Pac. J. Allergy Immunol."},{"key":"10.1016\/j.ejphar.2020.173568_bib115","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104793","article-title":"Remdesivir and SARS-CoV-2: structural requirements at both nsp12 RdRp and nsp14 Exonuclease active-sites","author":"Shannon","year":"2020","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejphar.2020.173568_bib116","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-019-13940-6","article-title":"Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV","volume":"11","author":"Sheahan","year":"2020","journal-title":"Nat. Commun."},{"issue":"541","key":"10.1016\/j.ejphar.2020.173568_bib117","doi-asserted-by":"crossref","first-page":"eabb5883","DOI":"10.1126\/scitranslmed.abb5883","article-title":"An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice","volume":"12","author":"Sheahan","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ejphar.2020.173568_bib118","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jare.2020.03.005","article-title":"COVID-19 infection: origin, transmission, and characteristics of human coronaviruses","volume":"24","author":"Shereen","year":"2020","journal-title":"J. Adv. Res."},{"key":"10.1016\/j.ejphar.2020.173568_bib119","doi-asserted-by":"crossref","first-page":"283","DOI":"10.3390\/v10060283","article-title":"Saracatinib inhibits middle east respiratory syndrome-coronavirus replication in vitro","volume":"10","author":"Shin","year":"2018","journal-title":"Viruses"},{"key":"10.1016\/j.ejphar.2020.173568_bib120","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107512","article-title":"Favipiravir, an anti-influenza drug against life-threatening RNA virus infections","author":"Shiraki","year":"2020","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejphar.2020.173568_bib121","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.virol.2017.11.012","article-title":"Wild-type human coronaviruses prefer cell-surface TMPRSS2 to endosomal cathepsins for cell entry","volume":"517","author":"Shirato","year":"2018","journal-title":"Virology"},{"key":"10.1016\/j.ejphar.2020.173568_bib122","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1093\/jac\/dkp274","article-title":"Intracellular metabolism of favipiravir (T-705) in uninfected and influenza A (H5N1) virus-infected cells","volume":"64","author":"Smee","year":"2009","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ejphar.2020.173568_bib123","doi-asserted-by":"crossref","DOI":"10.4414\/smw.2020.20246","article-title":"Benign COVID-19 in an immunocompromised cancer patient - the case of a married couple","volume":"150","author":"Spezzani","year":"2020","journal-title":"Swiss Med. Wkly."},{"unstructured":"Srivatsan Padmanabhan, M., Potential Dual Therapeutic Approach against SARS-CoV-2\/covid-19 with Nitazoxanide and Hydroxychloroquine.","key":"10.1016\/j.ejphar.2020.173568_bib124"},{"key":"10.1016\/j.ejphar.2020.173568_bib125","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1002\/jmv.25870","article-title":"COVID-19: herd immunity and convalescent plasma transfer therapy","volume":"92","author":"Syal","year":"2020","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.ejphar.2020.173568_bib126","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ijcard.2020.03.063","article-title":"The cardiovascular burden of coronavirus disease 2019 (COVID-19) with a focus on congenital heart disease","volume":"309","author":"Tan","year":"2020","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ejphar.2020.173568_bib127","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.msard.2017.12.002","article-title":"Treatment for paraneoplastic neuromyelitis optica spectrum disorder (NMOsd): probable effects of tocilizumab for both cancer and NMOsd","volume":"20","author":"Tanaka","year":"2018","journal-title":"Mult Scler. Relat. Disord."},{"year":"2019","author":"Tchesnokov","series-title":"Mechanism of Inhibition of Ebola Virus RNA-dependent RNA Polymerase by Remdesivir","key":"10.1016\/j.ejphar.2020.173568_bib128"},{"key":"10.1016\/j.ejphar.2020.173568_bib129","doi-asserted-by":"crossref","first-page":"326","DOI":"10.3390\/v11040326","article-title":"Mechanism of inhibition of Ebola virus RNA-dependent RNA polymerase by remdesivir","volume":"11","author":"Tchesnokov","year":"2019","journal-title":"Viruses"},{"year":"2014","author":"Trompiz","series-title":"First French Ebola Patient Leaves Hospital","key":"10.1016\/j.ejphar.2020.173568_bib130"},{"year":"2020","author":"Uno","series-title":"Camostat Mesilate Therapy for COVID-19. Internal and Emergency Medicine, 1-2","key":"10.1016\/j.ejphar.2020.173568_bib131"},{"issue":"17","key":"10.1016\/j.ejphar.2020.173568_bib132","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1056\/NEJMsr2005760","article-title":"Renin\u2013angiotensin\u2013aldosterone system inhibitors in patients with Covid-19","volume":"382","author":"Vaduganathan","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2020.173568_bib133","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1111\/tmi.13383","article-title":"The COVID-19 epidemic","volume":"25","author":"Velavan","year":"2020","journal-title":"Trop. Med. Int. Health"},{"key":"10.1016\/j.ejphar.2020.173568_bib134","doi-asserted-by":"crossref","DOI":"10.3201\/eid2607.200275","article-title":"Clinical management of Argentine hemorrhagic fever using ribavirin and favipiravir, Belgium, 2020","volume":"26","author":"Veliziotis","year":"2020","journal-title":"Emerg. Infect. Dis."},{"issue":"2","key":"10.1016\/j.ejphar.2020.173568_bib135","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.cell.2020.02.058","article-title":"Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein","volume":"181","author":"Walls","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.ejphar.2020.173568_bib136","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1056\/NEJMoa012354","article-title":"Lopinavir\u2013ritonavir versus nelfinavir for the initial treatment of HIV infection","volume":"346","author":"Walmsley","year":"2002","journal-title":"N. Engl. J. Med."},{"year":"2020","author":"Wampler Muskardin","series-title":"Intravenous Anakinra for Macrophage Activation Syndrome May Hold Lessons for Treatment of Cytokine Storm in the Setting of COVID19","key":"10.1016\/j.ejphar.2020.173568_bib137"},{"issue":"11","key":"10.1016\/j.ejphar.2020.173568_bib138","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1093\/infdis\/jiaa150","article-title":"Characteristics of peripheral lymphocyte subset alteration in COVID-19 pneumonia","volume":"221","author":"Wang","year":"2020","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.ejphar.2020.173568_bib139","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/nature17180","article-title":"Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys","volume":"531","author":"Warren","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.ejphar.2020.173568_bib140","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.bbi.2020.03.031","article-title":"Nervous system involvement after infection with COVID-19 and other coronaviruses","volume":"87","author":"Wu","year":"2020","journal-title":"Brain Behav. Immun."},{"issue":"15","key":"10.1016\/j.ejphar.2020.173568_bib142","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1093\/cid\/ciaa351","article-title":"Factors associated with prolonged viral RNA shedding in patients with COVID-19","volume":"71","author":"Xu","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ejphar.2020.173568_bib144","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ijid.2020.03.017","article-title":"Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis","volume":"94","author":"Yang","year":"2020","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.ejphar.2020.173568_bib143","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ijid.2020.03.022","article-title":"Clinical features and dynamics of viral load in imported and non-imported patients with COVID-19","volume":"94","author":"Xu","year":"2020","journal-title":"Int. J. Infect. Dis."},{"issue":"5","key":"10.1016\/j.ejphar.2020.173568_bib141","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1021\/acsinfecdis.0c00052","article-title":"Broad spectrum antiviral agent niclosamide and its therapeutic potential","volume":"6","author":"Xu","year":"2020","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.ejphar.2020.173568_bib145","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.yjmcc.2020.04.003","article-title":"More evidence is urgently needed to confirm the relation between angiotensin-converting enzyme inhibitors and COVID-19","volume":"141","author":"Yang","year":"2020","journal-title":"J. Mol. Cell. Cardiol."},{"year":"2020","author":"Yao","series-title":"In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)","key":"10.1016\/j.ejphar.2020.173568_bib146"},{"key":"10.1016\/j.ejphar.2020.173568_bib147","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.7150\/ijbs.45134","article-title":"COVID-19: what has been learned and to be learned about the novel coronavirus disease","volume":"16","author":"Yi","year":"2020","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.ejphar.2020.173568_bib148","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00766-18","article-title":"Orally efficacious broad-spectrum ribonucleoside analog inhibitor of influenza and respiratory syncytial viruses","volume":"62","author":"Yoon","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"issue":"15","key":"10.1016\/j.ejphar.2020.173568_bib149","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1001\/jama.2020.3204","article-title":"Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore","volume":"323","author":"Young","year":"2020","journal-title":"Jama"},{"year":"2020","author":"Yu","series-title":"Clinical Characteristics of Coronavirus Disease 2019 in Hangzhou, China: the Combination of Lopinavir\/ritonavir, Interferon, and Arbidol May Be a Well Choice for Antiviral Therapy in Common Cases","key":"10.1016\/j.ejphar.2020.173568_bib150"},{"key":"10.1016\/j.ejphar.2020.173568_bib151","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/jac\/dkh029","article-title":"Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients","volume":"53","author":"Zeldin","year":"2004","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ejphar.2020.173568_bib152","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105954","article-title":"The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality","author":"Zhang","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.ejphar.2020.173568_bib153","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1007\/s00134-020-05985-9","article-title":"Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target","volume":"46","author":"Zhang","year":"2020","journal-title":"Intensive Care Med."},{"key":"10.1016\/j.ejphar.2020.173568_bib154","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1182\/bloodadvances.2020001907","article-title":"First case of COVID-19 in a patient with multiple myeloma successfully treated with tocilizumab","volume":"4","author":"Zhang","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.ejphar.2020.173568_bib155","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.antiviral.2018.01.011","article-title":"Successful treatment of Marburg virus with orally administrated T-705 (Favipiravir) in a mouse model","volume":"151","author":"Zhu","year":"2018","journal-title":"Antivir. Res."},{"issue":"1","key":"10.1016\/j.ejphar.2020.173568_bib156","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1016\/j.jinf.2020.03.060","article-title":"Arbidol monotherapy is superior to lopinavir\/ritonavir in treating COVID-19","volume":"81","author":"Zhu","year":"2020","journal-title":"J. Infect."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299920306609?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299920306609?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T22:45:00Z","timestamp":1757976300000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299920306609"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":156,"alternative-id":["S0014299920306609"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2020.173568","relation":{},"ISSN":["0014-2999"],"issn-type":[{"type":"print","value":"0014-2999"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A review of medications used to control and improve the signs and symptoms of COVID-19 patients","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2020.173568","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2020 Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"173568"}}